NovoCure Ltd has evaluated the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients. When used in combination with standard chemotherapy, the Novo-TTF, a non-invasive medical device that uses low intensity alternating electric fields to destroy cancer cells, enhanced the anti-tumor effects of standard chemotherapy, thus prolonging time to disease progression and extending survival. Patients in the study did not experience any device-related, systemic, adverse events.

Asuragen, Inc. has announced that the Signature(R) LTx v2.0 Leukemia Translocation Panel was released as a “Conformite Europeenne” or “European Conformity” CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The CE-marked Signature(R) LTx v2.0 is a qualitative in vitro diagnostic device for use in a clinical laboratory to identify specific fusion transcripts in total RNA from whole blood or bone marrow to aid in the clinical diagnosis of translocation positive leukemias. Clinical validation studies showed 100% diagnostic accuracy in comparison to standard cytogenetic methods. This represents the world’s first Luminex-based molecular oncology IVD product.